磷脂酰肌酶3激酶催化亚基突变与乳腺癌^18F-FDG摄取的关系及其预测新辅助治疗疗效的前瞻性研究  

The association of phosphoinositide-3-kinase catalyticsubunit mutation with ^18F-FDG uptake and prediction of pathologic response after neoadjuvant chemotherapy in breast cancer

作　　者：李学瑞[1] 王淑侠[2] 李振中[3] 温灵珠[1] 龙晓雨[4] 陈宇[5] 郭子柏[6] 张国淳[1] 祖健[1] 

机构地区：[1]广东省人民医院广东省医学科学院肿瘤中心乳腺科,广州510080 [2]广东省人民医院广东省医学科学院核医学科,广州510080 [3]广东省人民医院广东省医学科学院药学部,广州510080 [4]广东省人民医院广东省医学科学院病理科,广州510080 [5]广东省人民医院广东省医学科学院医学研究中心,广州510080 [6]广东省中山市人民医院乳腺科,中山528403

出　　处：《中华实验外科杂志》2016年第9期2193-2195,共3页Chinese Journal of Experimental Surgery

基　　金：广东省自然科学基金（S2013010014851）

摘　　要：目的 探讨乳腺癌中磷脂酰肌酶3激酶催化亚基（PI3KCA）突变和^18F-FDG正电子发射显像（PET）/CT的摄取（SUV）率以及新辅助化疗疗效的关系.方法 测定71例原发性乳腺癌患者PI3KCA突变率,并分析其和^18F-FDG摄取率及新辅助化疗疗效之间的关系.结果 PI3KCA突变率高的患者,其^18F-FDG摄取率较PI3KCA突变率低的患者相对较高（平均SUV值分别为17.3和8.4,P＜0.05）.但PI3KCA突变率高的乳腺癌患者,其新辅助化疗疗效低于未突变的患者（获得病理完全缓解比率分别为20.0％和65.2％,P＜0.05）.同时,PI3KCA突变率高的患者无病生存时间显著低于未突变的患者（总生存时间分别为21.3个月和43.6个月,P＜0.05）.结论 PI3KCA突变与18F-FDG摄取率正相关,而与新辅助化疗的疗效负相关,是乳腺癌患者预后不良的因子之一。Objective To explore the association between phosphoinositide-3-kinase catalyticsubunit （PI3KCA） mutation and the uptake of ^18F-FDG positron emission tomography （PET）/CT and prediction of pathologic response after neoadjuvant chemotherapy in breast cancer.Methods The PI3KCA mutation rate in 71 breast cancer cases was examined.Subsequently,its association with the uptake of ^18F-FDG PET/CT and prediction of pathologic response after neoadjuvant chemotherapy was analyzed.Results The patients with high PI3KCA mutation rate had a higher uptake of ^18F-FDG PET/CT but lower pathologic response after neoadjuvant chemotherapy than in those with lower PI3KCA mutation rate （SUV was 17.3 and 8.4;pathological complate response （pCR） rate was 20.0% and 65.2%,respectively）.In addition,the patients with higher PI3KCA nutation rate had shorter disease-free survival time than in those with lower PI3KCA mutation rate.Conclusion High PI3KCA mutation was positively associated with uptake of 18F-FDG PET/CT,but negatively associated with pathologic response after neoadjuvant chemotherapy.The high PI3KCA mutation was considered to be an unfavorable factor in predicting the prognostic of breast cancer.

关 键 词：磷脂酰肌酶3激酶催化亚基 ^18F-FDG摄取率 新辅助化疗 乳腺癌 

分 类 号：R730.44[医药卫生—肿瘤]